Secondary immune-mediated thrombotic thrombocytopenic purpura in idiopathic inflammatory myopathy: a case-based review

Rheumatol Int. 2023 Mar;43(3):551-557. doi: 10.1007/s00296-022-05260-8. Epub 2022 Dec 28.

Abstract

Immune-mediated thrombotic thrombocytopenic purpura (iTTP) is a potentially fatal acquired thrombotic microangiopathy syndrome that frequently develops in the context of infectious diseases or systemic autoimmune conditions including connective tissue diseases. We report the case of a 42-year-old female suffering from severe iTTP associated with anti-Jo-1 positive antisynthetase syndrome, which was successfully treated with combination therapy of intravenous immune globulin, rituximab and plasma exchange. Based on a systematic review of the literature, two additional cases of idiopathic inflammatory myopathy-associated iTTP (secondary iTTP) were identified. In conclusion, iTTP may be a rare complication of IIM that clinicians should consider in cases of marked thrombocytopenia. Further work-up of this finding should include a peripheral blood smear (schistocyte count) and ADAMTS13 activity. The concomitant manifestation of these autoimmune conditions may require intensive immunosuppressive therapy.

Keywords: ADAMTS13 protein; Antisynthetase syndrome; Myositis; Thrombocytopenia; Thrombotic microangiopathy.

Publication types

  • Case Reports
  • Review

MeSH terms

  • Adult
  • Autoimmune Diseases* / complications
  • Female
  • Humans
  • Myositis* / complications
  • Purpura, Thrombotic Thrombocytopenic* / complications
  • Purpura, Thrombotic Thrombocytopenic* / therapy
  • Rituximab

Substances

  • Rituximab

Supplementary concepts

  • Thrombotic thrombocytopenic purpura, acquired